ARZERRA—Demonstrated Efficacy in First-Line CLL and FA-Refractory CLL1

ARZERRA® (ofatumumab) is indicated:

  • In combination with chlorambucil or bendamustine for the treatment of patients with chronic lymphocytic leukemia (CLL) who have not received prior therapy and who are not eligible for fludarabine-based therapy
  • For the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab
FA=fludarabine and alemtuzumab.
Reference: 1. Arzerra® (ofatumumab) summary of product characteristics. West Sussex, UK; Novartis Europharm Limited; 2015.